Zacks Investment Research upgraded shares of MESA LABS INC (MLAB) from NEUTRAL to OUTPERFORM on November 27, 2012, with a target price of $52.20.
MESA LABORATORIES, INC. designs, develops, acquires, manufactures and markets instruments and systems utilized in connection with industrial applications and hemodialysis therapy.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MESA LABS INC (MLAB),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment